Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

[/toggle]

Cempra $CEMP shares initially soared on Monday amid heavy trading volume in response to the FDI’s Ad Comm vote on solithromycin. However, the stock gave up all of its gains in regular trading to finish more than 9% lower, taking its losses in the last three trading sessions to more than 63%. The vote, which the drug-maker got on Friday, was on whether the treatment’s benefits outweigh the risks. The company managed to get the vote in its favor just by a whisker. Solithromycin is a next-generation antibiotic called a fluoroketolide, a member of a class of drugs that has demonstrated efficacy against drug-resistant bacteria because of their ability to bind to two sites on the bacterial ribosome.

Bayer submits marketing applications for regorafenib-Bayer $BAYRY filed marketing applications in the U.S., Europe, and Japan seeking approval of Stivarga (regorafenib) for the second-line treatment of patients with hepatocellular carcinoma (HCC), the third type of cancer for the Kinase inhibitor. It has approval for the treatment of metastatic cancer and metastatic gastrointestinal stromal tumors. The data supporting the marketing applications were generated in the Phase Clinical Trial, RESORCE. The study demonstrated HCC patients who progressed during the treatment with Nexavar (sorafenib), who received regorafenib experienced, considerably improved overall survival (OS) compared to placebo with 37% less risk of death.

 The Medicines Company terminates development of treatment for atherosclerotic plaque-The Medicines Company $MDCO fell in afterhours amid average trading volume in response to its announcement that it has dismissed development of MDCO-216, an investigational cholesterol efflux promoter that it once supposed had therapeutics potential for lowering atherosclerotic plaque.

 Biogen and Ionis Pharma’s Late-stage study on SMA successful- Ionis Pharmaceuticals $IONS and global licensee Biogen $BIIB gained sharply in response to the news that a Phase 3 study, CHERISH, evaluating SPINRAZA (nusinersen) in patients with later-onset (consistent with Type 2) spinal muscular atrophy (SMA) met its primary endpoint during the interim assessment. The study showed that children treatedwith nusinersen experienced a statistically substantial improvement in motor function compared to those who did not receive treatment.   Biogen intends to share the results with global regulatory authorities as soon as feasible. It filed marketing applications in the U.S. and Europe in late October, both are under accelerated review.

The FDA approved Teva Pharmaceuticals Industries’ $TEVA generic version of Daiichi Sankyo’s $DSKYF, $DSNKY,- TRIBENZOR (olmesartan medoxmil, amlodipine, hydrochlorothiazide) for the treatment of hypertension. Final launch preparations are in progress. The company recently launched its generic version of Daiichi’s AZOR (amlodipine and olmesartan medoxomil) in the U.S. market.

Koninklijke Philips N.V. $PHG agreed to pay Masimo International SARL $MASI, $300 million to settle their legal wrangling related to the infringement of two Masimo patents covering technology used help measure blood oxygen and track pulse rates. The settlement agreement also includes a clause which makes firms to collaborate together to integrate Masimo’s technologies into additional Philips products and to jointly develop certain other products. Masimo intends to use some of the after-tax proceeds to repay debts under its credit revolver.

Lexicon Pharmaceuticals $LXRX bagged exclusive research, development, and commercialization rights to LX9211 (BMS-986176), a candidate for the treatment of neuropathic pain that was jointly developed with Bristol-Myers Squibb $BMY under their December 2003 neuroscience drug discovery alliance agreement. This exclusivity also applies to other small molecules that act on the same target.

No secondary offerings to report.

No IPOs to report.

Depomed $DEPO reported Q3 revenue of $110.5 million, a growth of 5.3%, Y-o-Y. Product sales increased 5.3%, Y-o-Y to $110.3 million. Net income was -$12.9 million, a drop of 9.3%. Non-GAAP net income was $20.9 million, a drop of 16.1%, Y-o-Y.

SCYNEXIS $SCYX reported Q3 EPS of -$0.48, beating the guidance by $0.02. Revenue was $0.06 million, which was flat Y-o-Y, but missing the estimate by $0.01 million.

Nivalis Therapeutics $NVLS reported Q3 EPS of -$0.48, beating the guidance by $0.11. Cash, cash equivalents and marketable securities were $66.19 million.

Dermira $DERM reported Q3 EPS of -$0.72, which was in-line with the guidance, Revenue was $0.12 million, a drop of 98.4%, Y-o-Y.

Zogenix $ZGNX reported Q3 EPS of -$0.69, beating the guidance by $0.27. Revenue was $6.6 million, a drop of 27.6%, Y-o-Y, and beating the estimate by $3.5 million.

Kindred Biosciences $KIN reported Q3 EPS of -$0.29, beating the guidance by $0.04. Cash and cash equivalents were at $62.5 million, at the end of the concluded quarter.

Ritter Pharmaceuticals $RTTR reported Q3 EPS of -$0.41, surpassing the guidance by $0.09. At the end of the concluded quarter, cash and cash equivalents were $8.5 million.

Concordia International $CXRX reported Q3 revenue of $185.5 million, a growth of 99.5%, Y-o-Y. Net income from continuing operations were $75.1 million. Non-GAAP net income was $35.6 million, a drop of 26.1%, Y-o-Y.

Dynavax $DVAX reported Q3 EPS of -$90, missing the guidance by $0.15. Revenue was $0.16 million, a drop of 86.6%, Y-o-Y and missing the estimate by $2.28 million. As of September 30, 2016, the company had $109.6 million in cash, cash equivalents and marketable securities compared to $196.1 million at December 31, 2015.

BioCryst Pharmaceuticals $BCRX reported Q3 EPS of -$0.16, beating the estimate by $0.08. Revenue was $7.76 million, a drop of 29.4% Y-o-Y, but beating the guidance by $1.82 million.

Galmed $GLMD reported Q3 EPS of -$0.34, beating the guidance by $0.05. Revenue was $0.19 million.

Company (Ticker) Brokerage Action Recommendation Price Target My Price Target
Adamas Pharmaceuticals $ADMS Mizuho Reiterate Buy $26 N/A
Akorn $AKRX Deutsche Bank Upgrade From Hold to Buy N/A N/A
Akorn $AKRX WallachBeth Capital Downgrade/Price Target Cut From Buy to Hold From $40 to $22 N/A
Akorn $AKRX Bank of America Corp. Downgrade From Buy to Underperform $22 N/A
Alder Biopharmaceuticals $ALDR Aegis Initiation Buy N/A N/A
Alnylam Pharmaceuticals $ALNY Credit Suisse Group Reiterate Buy $50 N/A
Alexion Pharmaceuticals $ALXN Leerink Swann Reiterate Buy N/A N/A
Alexion Pharmaceuticals $ALXN Credit Suisse Group Reiterate Buy $165 N/A
AMAG Pharmaceuticals $AMAG Guggenheim Initiation Buy $42 N/A
Amgen $AMGN Mizuho Initiation Buy N/A $250
Biota Pharmaceuticals $AVIR FBR & Co. Reiterate Buy N/A N/A
AxoGen $AXGN WedBush Price Target Raised Outperform From $10 to $12 N/A
AstraZeneca $AZN Citigroup Reiterate Buy N/A N/A
Biogen $BIIB Mizuho Initiation Neutral N/A $420
Biogen $BIIB Leerink Swann Upgrade From Market Perform to Outperform N/A $420
Biogen $BIIB Piper Jaffray Cos. Upgrade From Neutral to Overweight $335 $420
Bluebird Bio $BLUE JPMorgan Chase & Co. Reiterate Buy N/A N/A
Bluebird Bio $BLUE Leerink Swann Reiterate Outperform $80 N/A
Bluebird bio $BLUE BTIG Research Reiterate Buy $83 N/A
BioMarin Pharmaceutical $BMRN Credit Suisse Group Reiterate Buy $111 N/A
BioMarin Pharmaceutical $BMRN Piper Jaffray Cos. Downgrade/Price Target Cut From Overweight to Neutral From $105 to $84 N/A
Celgene $CELG Mizuho Initiation Buy N/A $140
Cempra $CEMP Jefferies Group Downgrade/Price Target Cut From Buy to Hold From $36 to $10 Under Review
Cempra $CEMP Gabelli Downgrade From Buy to Hold N/A N/A
Cempra $CEMP Needham & Company Price Target Cut Buy From $36 to $15 N/A
Coherus Biosciences $CHRS Citigroup Reiterate Buy N/A N/A
Gilead Sciences $GILD Mizuho Initiation Buy N/A $130
Galmed Pharmaceuticals $GLMD HC Wainwright Reiterate Buy N/A N/A
Intercept Pharmaceuticals $ICPT Robert W. Baird Reiterate Outperform $332 N/A
Inovio Pharmaceuticals $INO Aegis Initiation Buy $12 N/A
Lion Biotechnologies $LBIO Jefferies Group Reiterate Buy $13 N/A
MacroGenics $MGNX BTIG Research Reiterate Buy $35 N/A
Nektar Therapeutics $NKTR Jefferies Group Price Target Raised N/A $15 N/A

Flex Pharma $FLKS- Christoph H. Westphal, President & CEO, bought 8,870 shares at $5.70. Westphal now owns 3,934,118 shares of FLKS. John P. McCabe, VP of Finance & Treasurer, bought 1,650 shares at $6.01. McCabe now owns 1,650 shares of FLKS.

Alexion Pharmaceuticals $ALXN- Leonard Bell, Director, sold 37,317 shares in two separate transactions. Bells sold 36,649 shares at $140.34; and 668 shares at $142.40. Bell still owns 404,287 shares of ALXN.

Pfizer $PFE- Albert Bourla, Group President, sold 18,390 shares at $30.05. The total value of the transaction was $552,530. Bourla still owns 130,809 shares of PFE.

No management changes and additions to report.

NYSE- Pumba Biotechnology $PBYI shares were among the major movers on the NYSE. The stock closed 7.04% higher. Axovant Sciences $AXON ended the day 6.65% higher.

NASDAQ- Amicus Therapeutics $FOLD shares were among the major gainers on the NASDAQ. The stock closed 21.01% higher. Ionis Pharmaceuticals $IONS ended the day 18.39% higher. Flex Pharma $FLKS ended the day 15.64% higher. Concordia International $CXRX shares were among the major losers on the NASDAQ. The stock closed 38.36% lower. Chiasma $CHMA ended the day 9.30% lower. Strongbridge Biopharma $SBBP ended the day 9.30% lower.

NYSEMKT- Actinium Pharmaceuticals $ATNM shares were among the major movers on the NYSEMKT. The stock closed 4.30% lower.

OTC- Amarantus Bioscience Holdings $AMBS shares were among the major movers on the OTC market. The stock closed 7.37% higher.

Company (Ticker) Short Interest as a % of Float % Change Days to Cover
Idera Pharmaceuticals $IDRA 11.6% -13% 4
Ignyta $RXDX 2.7% 0.9% 7
Illumina $ILMN 3.7% 4.8% 2
ImmuCell Corporation $ICCC 0.2% 98.6% 2
Immune Design $IMDZ 7.7% 8.4% 8
Immune Pharmaceuticals $IMNP 5.8% 24.3% 3
ImmunoGen $IMGN 16.4% 3.6% 14
Immunomedics $IMMU 20.8% -18.7% 5